UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $20.93 Million Holdings in Bruker Co. (NASDAQ:BRKR)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Bruker Co. (NASDAQ:BRKR - Free Report) by 17.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 356,969 shares of the medical research company's stock after acquiring an additional 52,214 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.24% of Bruker worth $20,926,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. London Co. of Virginia increased its holdings in shares of Bruker by 78.4% during the fourth quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company's stock valued at $245,820,000 after acquiring an additional 1,843,294 shares in the last quarter. Brown Advisory Inc. raised its holdings in shares of Bruker by 10.1% during the 4th quarter. Brown Advisory Inc. now owns 2,026,712 shares of the medical research company's stock worth $118,806,000 after acquiring an additional 185,912 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Bruker by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 2,013,741 shares of the medical research company's stock worth $118,081,000 after acquiring an additional 20,273 shares in the last quarter. FIL Ltd increased its position in shares of Bruker by 262.3% during the 4th quarter. FIL Ltd now owns 1,961,416 shares of the medical research company's stock valued at $114,978,000 after purchasing an additional 1,420,102 shares during the last quarter. Finally, Sculptor Capital LP increased its position in shares of Bruker by 484.1% during the 4th quarter. Sculptor Capital LP now owns 1,714,015 shares of the medical research company's stock valued at $100,476,000 after purchasing an additional 1,420,569 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors.

Bruker Stock Down 1.7%

Shares of BRKR traded down $0.63 during mid-day trading on Friday, reaching $36.63. The company's stock had a trading volume of 1,470,266 shares, compared to its average volume of 1,612,795. The business has a fifty day moving average of $38.62 and a 200 day moving average of $48.92. The company has a market cap of $5.55 billion, a price-to-earnings ratio of 48.20, a price-to-earnings-growth ratio of 2.16 and a beta of 1.23. Bruker Co. has a 1 year low of $34.10 and a 1 year high of $72.94. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15.

Bruker (NASDAQ:BRKR - Get Free Report) last released its earnings results on Wednesday, May 7th. The medical research company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. The business had revenue of $801.40 million during the quarter, compared to analysts' expectations of $763.83 million. During the same quarter last year, the company earned $0.53 earnings per share. The firm's revenue was up 11.0% on a year-over-year basis. As a group, analysts forecast that Bruker Co. will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Monday, June 16th will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.55%. The ex-dividend date is Monday, June 16th. Bruker's dividend payout ratio (DPR) is 38.46%.

Analysts Set New Price Targets

Several equities research analysts have weighed in on BRKR shares. Guggenheim reiterated a "buy" rating on shares of Bruker in a report on Monday, February 24th. Barclays cut their price objective on Bruker from $50.00 to $46.00 and set an "overweight" rating on the stock in a report on Thursday, May 8th. Stifel Nicolaus dropped their target price on Bruker from $57.00 to $48.00 and set a "hold" rating on the stock in a report on Thursday, May 8th. Wells Fargo & Company dropped their price objective on Bruker from $75.00 to $60.00 and set an "overweight" rating on the stock in a report on Thursday, April 17th. Finally, The Goldman Sachs Group decreased their target price on Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. Six analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, Bruker presently has an average rating of "Hold" and a consensus target price of $59.10.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.